



---

## Viral and bacterial causes for Alzheimer's disease: increasing evidence for a major role of infectious agents

G. Rajeswari<sup>1\*</sup>, A. Dishanth<sup>2</sup>, G. Rupa<sup>2</sup>, M. Hari Priya<sup>2</sup> and P. Sowjanya<sup>2</sup>

<sup>1</sup>Department of Pharmacology, <sup>2</sup>Department of Pharmacy Practice, Saastra College of Pharmaceutical Education and Research, Varigonda, Nellore, India

*Received: 19-09-2017 / Revised Accepted: 18-10-2017 / Published: 01-11-2017*

---

### ABSTRACT


The growing experimental data points to chronic viral and bacterial infections are possible risk factors for AD disease. Virus and bacteria are normally latent in elderly brains but reactivates under certain conditions cause persistent CNS infections by continuous pathogen replication. In depth viral and microbial agents have been reported to produce molecular hallmark of neurodegeneration, such as production and deposit of misfold protein aggregates, synaptopathies and neuronal death. HSV1 DNA plays major evidence in viral AD. Chlamydia pneumonia antibodies present in brain tangles are major evidence in bacterial AD. The infections may be synergy with recognized risk factors such as aging, concomitant metabolic diseases and host specific genetic signature. This review will focus on the contribution given to neurodegeneration by Herpes simplex type-1 and Chlamydia pneumonia.

**Key Words:** Herpes simplex type-1, Neurodegeneration, Chlamydia pneumonia, Alzheimer's disease.

---

**Address for Correspondence:** G. Rajeswari, Department of Pharmacology, Saastra College of Pharmaceutical Education and Research, Varigonda, Nellore, India; Email id: Dishudishanth100@gmail.com

**How to Cite this Article:** G. Rajeswari, A. Dishanth, G. Rupa, M. Hari Priya and P. Sowjanya. Viral and bacterial causes for Alzheimer's disease: increasing evidence for a major role of infectious agents. World J Pharm Sci 2017; 5(11): 100-105.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which allows adapt, share and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. 

## INTRODUCTION

Alzheimer's disease (AD) is the most common cause of dementia in elderly. This condition occurs after 5<sup>th</sup> decade of life and its incidence progressively increases with advanced age. The exact cause is not known but few factors are implicated in its etiology which includes positive family history and deposition of A $\beta$  amyloid derived from amyloid precursor protein (APP) forming neuritic senile plaques and neurofibrillary tangles. AD is associated with neuronal loss and progressive synaptic dysfunction, accompanied by the deposition of amyloid-(A) peptide, a cleavage product of the amyloid-protein precursor (APP), and abnormal forms of tau protein, markers that have been used as diagnostic criteria for the disease<sup>[1,2]</sup>. These constitute the hallmarks of AD, but whether they are causes of AD or consequences of AD is unknown. We suggest that these are indicators of an infectious etiology. In the case of AD, it is often not realized that microbes can cause chronic as well as acute diseases; that some microbes can remain latent in the body with the potential for reactivation, the effects of which might occur years after initial infection. AD has emerged as a serious public health concern, placing an immense burden on the individual, family, community, and health care resources. When developing diagnoses and treatments of complex illnesses, like Alzheimer's disease, most of the battle lies in finding of causative agent.

The transitional period between normal cognitive functioning and dementia is referred to as Mild Cognitive Impairment (MCI)<sup>[11]</sup> the most common form, the one most likely to progress to AD, is amnesic MCI (a-MCI). Patients with a MCI present with memory deficits greater than would be expected based on age and education; however functional abilities remain relatively preserved and independence intact<sup>[12]</sup>. Estimates of the annual incidence of individuals with MCI progressing to dementia range from 5 to 15<sup>[13]</sup>. Regardless of this variation, annual conversion rate of those with MCI is far greater than the baseline incidence rate<sup>[14]</sup>.

Researchers and clinicians had worked on Alzheimer's disease (AD) and related topics, expressed their concern that one particular aspect of the disease has been neglected, even though treatment based on it might slow or arrest AD progression. They referred many studies, mainly on humans, implicating specific microbes in the elderly brain, notably herpes simplex virus type 1 (HSV1), Chlamydia pneumoniae, and several types of spirochaete, in the etiology of AD<sup>[3-6]</sup>. Fungal infection of AD brain<sup>[7,8]</sup> has also been described, as well as abnormal microbiota in AD patient

blood<sup>[9]</sup>. The first observations of HSV1 in AD brain were reported almost three decades ago<sup>[10]</sup>. The ever-increasing number of these studies (now about 100 on HSV1 alone) warrants re-evaluation of the infection and AD concept.

## VIRAL INFECTION AND ALZHEMERS DISEASE

HSV-1 is an ubiquitous neurotropic virus. On chronic and persistent exposure to HSV-1 it has been proposed as potential risk for AD. It may vary from country to country about 1/3<sup>rd</sup> of the population has recurrent clinical manifestations of HSV-1 infection. It affects around 56%-85% of world population. Epidemiological studies suggest that another potential risk factor for AD is the presence of the HSV-1 genome in post-mortem brain specimens from AD, particularly those who carry type IV allele gene that encodes apolipoprotein E4<sup>[15,16]</sup>. HSV-1 reactivation genes detected in the brains of patients with familial AD are associated with  $\beta$ -amyloid deposits in patients suffering from AD<sup>[17,18]</sup>. HSV-1 DNA has been found in amyloid plaques from the temporal and frontal cortices. Recently a large population based study showed that anti HSV-1 IgG antibodies which are the markers of primary or reactivated HSV-1 are the risk factor for HSV-1 infections<sup>[19]</sup>. HSV-1 infections are increased in elderly patients with positive titers of anti HSV-1 antibodies while it is not associated with anti HSV-1 IgG antibodies, which are markers of a lifelong infection. Finally genome wide association (GWA) studies have correlated individual brain susceptibility to HSV-1 infection with a genetic risk of AD<sup>[20,21]</sup>. Entry of HSV-1 into host cell is mediated by nectin-2. Nectin-2 is also known as herpes virus entry mediator-B or poliovirus receptor related protein-2, Apo lipoprotein-E particularly its 4<sup>th</sup> allele gene is established as genetic risk factor for AD, has also been shown to influence susceptibility to viral infections and spreading into neuronal cells variations in the outer mitochondrial damage induced by HSV-1 DNAase such as UL12.5 and other genes. Variations in genetic signature determine individual brain susceptibility to HSV-1 infection during ageing or pathogen driven damages leading to neurodegenerations.

## BACTERIAL INFECTIONS AND ALZHEMERS DISEASE

AD was first linked to *C.pneumoniae* infection based on the evidence that 90% of AD brains were found to be PCR-positive for *C.pneumoniae* pathogen, particularly in the cerebral regions most affected by AD<sup>[22]</sup>. This microorganism is able to infect microglia, astrocytes, perivascular

macrophages and myocytes<sup>[22,23]</sup>. The microorganism is isolated from the tissue as metabolically active and propagated in cells. Some studies failed to detect *C.pneumonia* in archival tissue of AD patients, but two of these studies were performed on tissue that was paraffin embedded, which may have effected the organism identification using specific PCR technique<sup>[24-26]</sup>. Other studies were performed on frozen tissue, and identified presence of *C.pneumoniae* in AD patient brain through PCR analysis. Recently, little et al demonstrated that *C.pneumoniae* in mice induced AD like hall marks in brains through intranasal inoculation. *C.pneumoniae* antibodies have been identified in AD brain, tangles and colocalizing with plaques in vulnerable brain regions<sup>[27]</sup>.

### EVIDENCE FOR INFECTION

1. In most of the elderly people, viruses and other microbes are present in the brain<sup>[28-30]</sup>. Usually dormant, reactivations occur after stress and immunosuppression. Eg: HSV1 DNA is amplified in the brain of immunocompromised patients<sup>[31]</sup>.
2. Herpes simplex encephalitis (HSE) damages localized regions of the CNS related to limbic system, associated with cognitive, memory and affective processes as well as personality<sup>[32]</sup>.
3. HSV infection revealed by seropositively is associated with development of AD<sup>[35-37]</sup>.
4. In brain of AD patients, pathogen signatures (Eg: HSV1 DNA) specifically colocalize with AD patients<sup>[30, 33, 34]</sup>.
5. AD is known to have a prominent inflammatory component characteristic of infection.
6. AD risk factors include polymorphisms in the apolipoprotein E (ApoE) gene (which modulates immune system) and susceptibility to infectious disease.
7. Genome-wide association studies reveal that immune system components including virus receptor genes are further AD risk factors.
8. Features of AD pathology are transmissible by inoculation of AD brain to primates and mice.

### GROWING EVIDENCE FOR MECHANISM: ROLE OF A $\beta$

- (i) Enzymatic product like 25-hydroxyl cholesterol, 25-OHC induces innate anti viral immunity and the gene encoding cholesterol 25-hydroxylase is selectively up regulated by virus infection<sup>[38, 39]</sup>.
- (ii) Polymorphisms in human CH25H govern both AD susceptibility and a deposition<sup>[40]</sup>,

arguing that A $\beta$  induction is likely to be among the targets of 25OHC, providing a potential mechanistic link between infection and A $\beta$  production<sup>[41]</sup>

- (iii) Potent activity against multiple bacteria is an A $\beta$  anti microbial peptide and yeast<sup>[42]</sup>. Also has antiviral activity<sup>[43, 44]</sup>.
- (iv) Antimicrobial peptide like (defensin1) is up regulated in AD brain<sup>[44]</sup>.

### EVIDENCE OF REACTIVATION OF HSV1 IN THE HUMAN CNS


The gross damage caused during HSE is far more readily detectable. A major problem in studying the role of HSV1 in AD is the current lack of a method for detecting reactivation of the virus particularly if, as postulated, it occurs on a limited scale or in very localized regions of the CNS outbreak. After the initial episode a number of case reports of HSE recurring during some month and years. It has been suggested that these might be fairly frequent occurrences of sub-clinical encephalitis because of the mildness might not be diagnosed correctly. HSV test was sent to a reference laboratory for analysis 3200 CSF specimens by Peter & several from the subjects with wide range of ages. They found that over-all, 26 were positive for HSV1 and 36 for HSV2, but in the over 60 age group, the ratio of HSV-2–HSV-1 infection was low, namely, 3:13, and 11 of the 13 HSV1-positive subjects were female. In the over 70 s, comprising 1 male, 10 female, 10 were positive for HSV-1, with 1 female positive for HSV2. Almost infections were detected in females than in male twice as many as HSV1 and HSV2. Female aged over 70 years data display commented on particular bias for HSV1 CNS infection an intriguing ending, in view of the preponderance of females with AD. Condition such as immunosuppressant strongly suggests that HSV1 reactivates in post-mortem human brain specimens under pre PCR study. By using a 3H-HSV1 probe incites hybridisation was examined in patients brain acute leukaemia who had been immune suppressed as part of the treatment. Strong labelling of indicating the presence of HSV1 DNA, was revealed in frontal and temporal cortices of those who were HSV-sero positive but not in those who were HSV-sero negative or who had not been immune suppressed<sup>[45]</sup>. Nov 2004 and December 2012 revealed that a review of multiple sclerosis patient was treated with natalizumab which hinders inflammatory cell migration into the CNS indicates the presence and reaction in patients brain with HSE under 20 cases which are developed.

### CONCLUSION

The evidence shows that presence of HSV1 for reactivation, its interference with cellular process,

its harmful effects on cognition is very strong in the elderly human brain. HSV1 is a very good support for being a causative factor in AD. The virus and bacteria induced effects add to and are possibly amplified by several factors such as metabolic disorders, genetic alterations and other environmental risk factors, involved in the pathogenesis of neurodegenerative diseases. As a result, the virus and bacteria induced damage

amplifies and accelerates the neurodegenerative process, whose signs are usually manifested during aging. The data reviewed in our paper suggest that more detailed understanding of the molecular mechanisms underlying virus and bacteria mediated neuronal damage may have the way to the identification of new preventive and/or therapeutic strategies aimed at counteracting the progression of these devastating pathologies.



Neurofibrillary tangles in Alzheimers Disease

## REFERENCE

- [1] Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van BG, Berg L The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology* (1991);41:479-486.
- [2] Braak H, Braak E Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol (Berl)*.(1991);82:239-259.
- [3] DeChiara G, Marcocci ME, Sgarbanti R, Civitelli L, Ripoli C, Piacentini R, Garaci E, Grassi C, Palamara AT Infectious agents and neurodegeneration. *Mol Neurobiol*. (2012);46:614-638.
- [4] Itzhaki RF Herpes simplex virus type 1 and Alzheimer's disease: Increasing evidence for a major role of the virus. *Front Aging Neurosci*.(2014);6:202.
- [5] Miklossy J Historic evidence to support a causal relationship between spirochetal infections and Alzheimer's disease *Front Aging Neurosci*.(2015);7:46.
- [6] Alonso R, Pisa D, Marina AI, Morato E, Rabano A, Carrasco L Fungal infection in patients with Alzheimer's disease. *J Alzheimers Dis*.(2014);41:301-311.
- [7] Pisa D, Alonso R, Rabano A, Rodal I, Carrasco L Different brain regions are infected with fungi in Alzheimer's disease. *Sci Rep*.(2015);5:15015.
- [8] Potgieter M, Bester J, Kell DB, Pretorius E, The dormant blood microbiome in chronic, inflammatory diseases. *FEMS Microbiol Rev*.(2015);39:567-591.
- [9] Jamieson GA, Maitland NJ, Wilcock GK, Craske J, Itzhaki RF, Latent herpes simplex virus type 1 in normal and Alzheimer's disease brains. *J Med Virol*.(1991);33:224-227.
- [10] Berchtold NC, Cotman CW. Evolution in the conceptualization of dementia and Alzheimer's disease: Greco-Roman period to the 1960s. *Neurobiol. Aging* 1998; 19 : 173–89.
- [11] Bachman DL, Wolf PA, Linn R, Knoefel JE, Cobb J, Belanger A, *et al*. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. *Neurology*. 1992;42:115-119
- [12] Association As, "Alzheimer's disease facts and figures.(2012).
- [13] J. M. Burns and J. C. Morris, John Wiley & Sons, *Mild Cognitive Impairment and Early Alzheimer's Disease: Detections and Diagnosis*.(2008),
- [14] Wozniak MA, Shipley SJ, Combrinck M *et al* Productive herpes simplex virus in brain of elderly normal subjects and Alzheimer's disease patients. *J Med Virol*.(2005); 75:300–306.

- [15] Itzhaki RF, Lin WR, Shang D et al Herpes simplex virus type1 in brain and risk of Alzheimer's disease. *Lancet*.(1997);349:241–244.
- [16] Mori I, Kimura Y, Naiki H et al Reactivation of HSV-1 in the brain of patients with familial Alzheimer's disease. *J Med Virol*.(2004);73:605–611.
- [17] Wozniak MA, Mee AP, Itzhaki RF Herpes simplex virus type1 DNA is located within Alzheimer's disease amyloid plaques. *J Pathol*.(2009);217:131–138.
- [18] Letenneur L, Peres K, Fleury H et al Seropositive to herpes virus antibodies and risk of Alzheimer's disease: a population-based cohort study. *Plos One*.(2008);3:e3637.
- [19] Lambert JC, Heath S, Even G et al Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. *Nat Genet*.(2009);41:1094–1099.
- [20] Porcellini E, Carbone I, Ianni M, Licastro F Alzheimer's disease gene signature says: beware of brain viral infections. *Immun Ageing*.(2010);7:16–20.
- [21] Balin BJ, Gerard HC, Arking EJ et al Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain. *Med Microbiol Immunol (Berl)*.(1998);187:23–42
- [22] MacIntyre A, Hammond CJ, Little CS et al Chlamydia pneumoniae infection alters the junctional complex proteins of human brain microvascular endothelial cells. *FEMS Microbiol Lett*.(2002);217:167–172.
- [23] D'Andrea MR, Nagele RG, Wang HY, Lee DH Consistent immunohistochemical detection of intracellular beta-amyloid42 in pyramidal neurons of Alzheimer's disease entorhinal cortex. *Neurosci Lett*.(2002);333:163–166.
- [24] Nochlin D, Shaw CM, Campbell LA, Kuo CC Failure to detect Chlamydia pneumoniae in brain tissues of Alzheimer's disease. *Neurology* (1999);53:1888.
- [25] Ring RH, Lyons JM Failure to detect Chlamydia pneumoniae in the late-onset Alzheimer's brain. *J Clin Microbiol*.(2000);38:2591–2594.
- [26] Hammond CJ, Hallock LR, Howanski RJ et al Immunohistological detection of Chlamydia pneumoniae in the Alzheimer's disease brain. *BMC Neurosci*.(2010); 11:121–132
- [27] Jamieson GA, Maitland NJ, Wilcock GK, Craske J, Itzhaki RF Latent herpes simplex virus type1 in normal and Alzheimer's disease brains. *J Med Virol*.(1991); 33: 224-227.
- [28] Miklossy J Alzheimer's disease – a spirochetosis? *Neuroreport* (1993); 4: 841-848.
- [29] Balin BJ, Gerard HC, Arking EJ, Appelt DM, Branigan PJ, Abrams JT, Whittum-Hudson JA, Hudson AP Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain. *Med Microbiol Immunol*.(1998);187:23-42.
- [30] Saldanha J, Sutton RN, Gannicliffe A, Farragher B, Itzhaki RF Detection of HSV1 DNA by in situ hybridisation in human brain after immunosuppression. *J Neurol Neurosurg Psychiatry*.(1986);49:613-619.
- [31] Miklossy J, Khalili K, Gern L, Ericson RL, Darekar P, Bolle L, Hurlimann J, Paster BJ *Borrelia burgdorferi* persists in the brain in chronic Lyme neuroborreliosis and may be associated with Alzheimer disease. *J Alzheimers Dis*.(2004);6:639-649.
- [32] Wozniak MA, Mee AP, Itzhaki RF Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques. *J Pathol*.(2009);217:131-138.
- [33] Letenneur L, Peres K, Fleury H, Garrigue I, Barberger Gateau P, Helmer C, Orgogozo JM, Gauthier S, Dartigues JF Seropositivity to herpes simplex virus antibodies and risk of Alzheimer's disease: A population-based cohort study. *PLoS One* 3, e3637. (2008).
- [34] Mancuso R, Baglio F, Cabinio M, Calabrese E, Hernis A, Nemni R, Clerici M Titers of herpes simplex virus type 1 antibodies positively correlate with grey matter volumes in Alzheimer's disease. *J Alzheimers Dis*.(2014);38:741-745.
- [35] L'ovheim H, Gilthorpe J, Johansson A, Eriksson S, Hallmans G, Elgh F Herpes simplex infection and the risk of Alzheimer's disease: A nested case-control study. *Alzheimers Dement*.(2015);11:587-592.
- [36] L'ovheim H, Gilthorpe J, Adolfsson R, Nilsson LG, Elgh F Reactivated herpes simplex infection increases the risk of Alzheimer's disease. *Alzheimers Dement*.(2015);11:593-599.
- [37] Blanc M, Hsieh WY, Robertson KA, Kropp KA, Forster T, Shui G, Lacaze P, Watterson S, Griffiths SJ, Spann NJ, Meljon A, Talbot S, Krishnan K, Covey DF, Wenk MR, Craigon M, Ruzsics Z, Haas J, Angulo A, Griffiths WJ, Glass CK, Wang Y, Ghazal P The transcription factor STAT-1 couples macrophage synthesis of 25-hydroxycholesterol to the interferon antiviral response. *Immunity*.(2013);38:106-118.
- [38] Liu SY, Aliyari R, Chikere K, Li G, Marsden MD, Smith JK, Pernet O, Guo H, Nusbaum R, Zack JA, Freiberg AN, Su L, Lee B, Cheng G Interferon-inducible cholesterol 25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. *Immunity*.(2013);38:92-105.

- [39] Papassotiropoulos A, Lambert JC, Wavrant-De Vrieze F, Wollmer MA, von der KH, Streffer JR, Maddalena A, Huynh KD, Wolleb S, Lutjohann D, Schneider B, Thal DR, Grimaldi LM, Tsolaki M, Kapaki E, Ravid R, Konietzko U, Hegi T, Pasch T, Jung H, Braak H, Amouyel P, Rogaeve EI, Hardy J, Hock C, Nitsch RM Cholesterol25-hydroxylase on chromosome 10 q13 is a susceptibility gene for sporadic Alzheimer's disease. *Neurodegener Dis*.(2005);233-241.
- [40] Lathe R, Sapronova S, Kotelevtsev Y Atherosclerosis and Alzheimer – diseases with a common cause? Inflammation, oxysterols, vasculature. *BMC Geriatrics*.(2014); 14:36.
- [41] SosciaSJ, KirbyJE, WashicoskyKJ, TuckerSM, Ingelsson M, Hyman B, Burton MA, Goldstein LE, Duong S, Tanzi RE, Moir RD The Alzheimer's disease-associated amyloidbeta-protein is an antimicrobial peptide. *PLoSOne*.(2010);5:e9505.
- [42] White MR, Kandel R, Tripathi S, Condon D, Qi L, Taubenberger J, Hartshorn KL Alzheimer's associated beta-amyloid protein inhibits influenza A virus and modulates viral interactions with phagocytes. *PLoS One*.(2014);9:e101364.
- [43] Bourgade K, Garneau H, Giroux G, Le Page AY, Bocti C, Dupuis G, Frost EH, Fulop T Jr Beta-amyloid peptides display protective activity against the human Alzheimer's disease-associated herpes simplex virus-1. *Biogerontology*.(2015);16:85-98.
- [44] Bourgade K, Le PA, Bocti C, Witkowski JM, Dupuis G, Frost EH, Fulop T Jr Protective effect of amyloidbeta peptides against herpes simplex virus-1 infection in a neuronal cell culture model. *J Alzheimers Dis*.(2016);50:12271 241.
- [45] Ball,M.J..Limbic predilectionin Alzheimer dementia: is reactivated herpes virus involved? *Can. J.Neurol.Sci*.(1982);9:303–306.